Vitrakvi (larotrectinib) is a medication used for the treatment of patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity and have no satisfactory alternative treatments or that have progressed following treatment.
Medicine approved by
European Medical Agency (EMA)
Food and Drug Administration (FDA)
- Over 1.2 million patients reached
- Over 11,000 patients helped
- 13,000 medicines supplied
- 100% success delivering to people in 85 countries
Safe and Secure
Capsules or oral solution
“I want to recommend everyone to work with this organization. They are reliable, honest, punctual and do everything to meet your needs…”
“Dr. Aysen Simsek and her team offered assistance during a very difficult time. I truly appreciate their quick, efficient and professional attitude, as well as their patience and superb customer service…”
“I highly recommend TheSocialMedwork. They welcomed me with open arms when I went to their office in Amsterdam. I was in a very difficult situation with a tight schedule, and their amazing team members…”
WWe are TheSocialMedwork, a registered medical intermediary that helps you access elsewhere approved medicines, no matter where you live. To date, we have assisted patients in over 80 countries to access thousands of life-improving medicines.Learn more
Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.